Evaxion A/S (NASDAQ:EVAX) Announces Quarterly Earnings Results

Evaxion A/S (NASDAQ:EVAX) issued its quarterly earnings data on Thursday. The company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.43), Zacks reports.

Here are the key takeaways from Evaxion A/S’s conference call:

• EVX-01 phase II translational data showed a 86% immunogenicity rate with 86% de novo T cell responses, and the company expects to report 3?year clinical outcome data in H2 2026.
• Evaxion demonstrated platform scalability to glioblastoma in collaboration with Duke—personalized vaccine designs were feasible for all 24 tumors, with 21/24 designs combining neoantigens and ERV antigens, supporting broader applicability beyond melanoma.
• In collaboration with the Gates Foundation, the company used AI?Immunology to design a novel polio vaccine concept (hybrid capsid plus de novo T?cell antigen), illustrating the platform’s ability to reinvent classical vaccines.
• Financial discipline preserved but runway is limited—cash and equivalents were $18.4M at quarter end, projected operational burn is roughly $14M for 2026, giving a runway into H2 2027 and implying potential need for financing absent partnerships.
• Management and business?development changes include promotion of Birgitte Rønø to CSO/COO and addition of a BD?focused board member, with multiple unspecified partnering discussions underway for both assets and the platform.

Evaxion A/S Stock Performance

Evaxion A/S stock traded up $0.27 during mid-day trading on Friday, reaching $4.34. The company’s stock had a trading volume of 36,792 shares, compared to its average volume of 34,738. The firm has a market cap of $36.20 million, a price-to-earnings ratio of -2.95 and a beta of 0.26. The business has a 50 day moving average price of $3.88 and a 200-day moving average price of $4.56. The company has a current ratio of 5.85, a quick ratio of 5.85 and a debt-to-equity ratio of 0.41. Evaxion A/S has a twelve month low of $1.46 and a twelve month high of $12.15.

Hedge Funds Weigh In On Evaxion A/S

A hedge fund recently bought a new stake in Evaxion A/S stock. Northwestern Mutual Wealth Management Co. acquired a new position in Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 8,000 shares of the company’s stock, valued at approximately $38,000. Northwestern Mutual Wealth Management Co. owned 0.10% of Evaxion A/S at the end of the most recent reporting period. 11.04% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have issued reports on EVAX. Lake Street Capital lowered their price objective on shares of Evaxion A/S from $11.00 to $9.00 and set a “buy” rating for the company in a research report on Monday, March 9th. Wall Street Zen downgraded shares of Evaxion A/S from a “buy” rating to a “hold” rating in a research report on Sunday, March 22nd. Weiss Ratings reissued a “sell (d-)” rating on shares of Evaxion A/S in a research report on Friday, January 9th. Maxim Group started coverage on shares of Evaxion A/S in a research report on Thursday, February 19th. They set a “buy” rating and a $10.00 price target for the company. Finally, HC Wainwright reissued a “buy” rating and set a $16.00 price target on shares of Evaxion A/S in a research report on Friday, April 24th. Five investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Evaxion A/S presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.00.

About Evaxion A/S

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.